Do inflammatory pathways drive melanomagenesis?

Samantha L. Schneider, Andrew L. Ross, James M Grichnik

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Inflammatory pathways serve to protect the host and promote tissue healing/repair; however, over-activation or dysregulation can be pathological with unintended consequences including malignant progression. A correlation between inflammation and cancer has been well established, and anti-inflammatory medications have been shown to be chemopreventive in certain malignancies. Data are now becoming available that outline an inflammatory pathway that may have a critical role in melanomagenesis. ATP-regulated membrane channels/receptors P2X7 and PANX1 have been directly implicated in melanoma tumor growth. Among other potential effects, opening of the P2X7/PANX1 channel results in activation of the NALP3 inflammasome, which in turn leads to caspase-1 activation and increased levels of activated IL-1β. Elevated levels of caspase-1 and IL-1β have been correlated with melanoma progression, and inhibitors of the inflammasome, caspase and IL-1β activity have all been shown to inhibit melanoma growth. Among many other potential actions, IL-1β increases cyclooxygenase-2 expression leading to local increases in inflammatory mediators such as prostaglandin E2 (PGE2). Anti-inflammatory medications targeting the end of this pathway have had positive results for certain cancers but overall remain mixed for melanoma. A better understanding of the pathways and appropriate intervention points may help direct future therapies. In this viewpoint, we will review data and attempt to model an inflammatory pathway that may be critical for melanomagenesis and propose future directions for exploration.

Original languageEnglish (US)
Pages (from-to)86-90
Number of pages5
JournalExperimental Dermatology
Volume24
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Interleukin-1
Caspase 1
Melanoma
Inflammasomes
Chemical activation
Neoplasms
Anti-Inflammatory Agents
Purinergic P2X7 Receptors
Cyclooxygenase 2
Growth
Ion Channels
Dinoprostone
Action Potentials
Tumors
Repair
Adenosine Triphosphate
Tissue
Inflammation
Therapeutics

Keywords

  • Melanoma
  • Stem cell
  • Tumor stem cell

ASJC Scopus subject areas

  • Dermatology
  • Molecular Biology
  • Biochemistry

Cite this

Schneider, S. L., Ross, A. L., & Grichnik, J. M. (2015). Do inflammatory pathways drive melanomagenesis? Experimental Dermatology, 24(2), 86-90. https://doi.org/10.1111/exd.12502

Do inflammatory pathways drive melanomagenesis? / Schneider, Samantha L.; Ross, Andrew L.; Grichnik, James M.

In: Experimental Dermatology, Vol. 24, No. 2, 01.02.2015, p. 86-90.

Research output: Contribution to journalArticle

Schneider, SL, Ross, AL & Grichnik, JM 2015, 'Do inflammatory pathways drive melanomagenesis?', Experimental Dermatology, vol. 24, no. 2, pp. 86-90. https://doi.org/10.1111/exd.12502
Schneider, Samantha L. ; Ross, Andrew L. ; Grichnik, James M. / Do inflammatory pathways drive melanomagenesis?. In: Experimental Dermatology. 2015 ; Vol. 24, No. 2. pp. 86-90.
@article{79e426705b6449de85638d4b0732df16,
title = "Do inflammatory pathways drive melanomagenesis?",
abstract = "Inflammatory pathways serve to protect the host and promote tissue healing/repair; however, over-activation or dysregulation can be pathological with unintended consequences including malignant progression. A correlation between inflammation and cancer has been well established, and anti-inflammatory medications have been shown to be chemopreventive in certain malignancies. Data are now becoming available that outline an inflammatory pathway that may have a critical role in melanomagenesis. ATP-regulated membrane channels/receptors P2X7 and PANX1 have been directly implicated in melanoma tumor growth. Among other potential effects, opening of the P2X7/PANX1 channel results in activation of the NALP3 inflammasome, which in turn leads to caspase-1 activation and increased levels of activated IL-1β. Elevated levels of caspase-1 and IL-1β have been correlated with melanoma progression, and inhibitors of the inflammasome, caspase and IL-1β activity have all been shown to inhibit melanoma growth. Among many other potential actions, IL-1β increases cyclooxygenase-2 expression leading to local increases in inflammatory mediators such as prostaglandin E2 (PGE2). Anti-inflammatory medications targeting the end of this pathway have had positive results for certain cancers but overall remain mixed for melanoma. A better understanding of the pathways and appropriate intervention points may help direct future therapies. In this viewpoint, we will review data and attempt to model an inflammatory pathway that may be critical for melanomagenesis and propose future directions for exploration.",
keywords = "Melanoma, Stem cell, Tumor stem cell",
author = "Schneider, {Samantha L.} and Ross, {Andrew L.} and Grichnik, {James M}",
year = "2015",
month = "2",
day = "1",
doi = "10.1111/exd.12502",
language = "English (US)",
volume = "24",
pages = "86--90",
journal = "Experimental Dermatology",
issn = "0906-6705",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Do inflammatory pathways drive melanomagenesis?

AU - Schneider, Samantha L.

AU - Ross, Andrew L.

AU - Grichnik, James M

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Inflammatory pathways serve to protect the host and promote tissue healing/repair; however, over-activation or dysregulation can be pathological with unintended consequences including malignant progression. A correlation between inflammation and cancer has been well established, and anti-inflammatory medications have been shown to be chemopreventive in certain malignancies. Data are now becoming available that outline an inflammatory pathway that may have a critical role in melanomagenesis. ATP-regulated membrane channels/receptors P2X7 and PANX1 have been directly implicated in melanoma tumor growth. Among other potential effects, opening of the P2X7/PANX1 channel results in activation of the NALP3 inflammasome, which in turn leads to caspase-1 activation and increased levels of activated IL-1β. Elevated levels of caspase-1 and IL-1β have been correlated with melanoma progression, and inhibitors of the inflammasome, caspase and IL-1β activity have all been shown to inhibit melanoma growth. Among many other potential actions, IL-1β increases cyclooxygenase-2 expression leading to local increases in inflammatory mediators such as prostaglandin E2 (PGE2). Anti-inflammatory medications targeting the end of this pathway have had positive results for certain cancers but overall remain mixed for melanoma. A better understanding of the pathways and appropriate intervention points may help direct future therapies. In this viewpoint, we will review data and attempt to model an inflammatory pathway that may be critical for melanomagenesis and propose future directions for exploration.

AB - Inflammatory pathways serve to protect the host and promote tissue healing/repair; however, over-activation or dysregulation can be pathological with unintended consequences including malignant progression. A correlation between inflammation and cancer has been well established, and anti-inflammatory medications have been shown to be chemopreventive in certain malignancies. Data are now becoming available that outline an inflammatory pathway that may have a critical role in melanomagenesis. ATP-regulated membrane channels/receptors P2X7 and PANX1 have been directly implicated in melanoma tumor growth. Among other potential effects, opening of the P2X7/PANX1 channel results in activation of the NALP3 inflammasome, which in turn leads to caspase-1 activation and increased levels of activated IL-1β. Elevated levels of caspase-1 and IL-1β have been correlated with melanoma progression, and inhibitors of the inflammasome, caspase and IL-1β activity have all been shown to inhibit melanoma growth. Among many other potential actions, IL-1β increases cyclooxygenase-2 expression leading to local increases in inflammatory mediators such as prostaglandin E2 (PGE2). Anti-inflammatory medications targeting the end of this pathway have had positive results for certain cancers but overall remain mixed for melanoma. A better understanding of the pathways and appropriate intervention points may help direct future therapies. In this viewpoint, we will review data and attempt to model an inflammatory pathway that may be critical for melanomagenesis and propose future directions for exploration.

KW - Melanoma

KW - Stem cell

KW - Tumor stem cell

UR - http://www.scopus.com/inward/record.url?scp=84928360985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928360985&partnerID=8YFLogxK

U2 - 10.1111/exd.12502

DO - 10.1111/exd.12502

M3 - Article

C2 - 25041143

AN - SCOPUS:84928360985

VL - 24

SP - 86

EP - 90

JO - Experimental Dermatology

JF - Experimental Dermatology

SN - 0906-6705

IS - 2

ER -